文献速递临床试验与 GCP流行病学与生物统计

多菌株益生菌预防印度低出生体重儿新生儿脓毒症的III期试验方案

Evaluating the efficacy of a multistrain probiotic supplementation for prevention of neonatal sepsis in 0-2-month-old low birth weight infants in India-the "ProSPoNS" Study protocol for a phase III, multicentric, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2021-04-01

BACKGROUND: Progress has been made in the reduction of under-five mortality in India; however, neonatal mortality is reducing at a slower rate. Efforts are required to bring down neonatal mortality in order to attain the Sustainable Development Goal-3.…

要点

  • 该试验为III期多中心随机双盲安慰剂对照设计,计划入组6144名低出生体重儿。
  • 主要结局为脓毒症和可能严重细菌感染(PSBI),随访60天。

核心结论

  • 该试验旨在回答益生菌能否预防低出生体重儿新生儿脓毒症,结果可推广至印度及其他中低收入国家。

研究设计与样本

  • III期、多中心、随机、双盲、安慰剂对照试验,在印度六个站点开展。
  • 计划入组6144名健康低出生体重儿,生后第一周内入组,按1:1随机,分层因素为站点、性别和出生体重。
  • 随机化通过交互式网络应答系统(IWRS)进行,随访60天。

关键数值与推荐

  • 主要结局为脓毒症和可能严重细菌感染(PSBI)。
  • 试验注册号:CTRI/2019/05/019197,注册日期2019年5月16日。

临床怎么用

  • 若试验证实有效,可为低出生体重儿预防新生儿脓毒症提供益生菌干预依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Progress has been made in the reduction of under-five mortality in India; however, neonatal mortality is reducing at a slower rate. Efforts are required to bring down neonatal mortality in order to attain the Sustainable Development Goal-3. Prevention of sepsis among the high-risk, vulnerable low birth weight neonates by a newer intervention with probiotic supplementation is promising. METHODS: A phase III, multicenter, randomized, double-blind, placebo-controlled study is being conducted at six sites in India. A total of 6144 healthy low birth weight (LBW) infants fulfilling the eligibility criteria would be enrolled within the first week of life, after obtaining written informed consent from the parents of the infant. Randomization in 1:1 ratio, stratified by site, sex, and birth weight, would be done through an interactive web response system (IWRS) using a standard web browser and email service. Vivomixx®, a probiotic containing a mix of 8 strains of bacteria, in a suspension form standardized to deliver 10 billion CFU/ml, or an organoleptically similar placebo would be fed to enrolled infants in a 1-ml/day dose for 30 days. The follow-up of enrolled infants for 60 days would take place as per a pre-specified schedule for recording morbidities and outcome assessments at the six participating sites. Screening for morbidities would be conducted by trained field workers in the community, and sick infants would be referred to designated clinics/hospitals. A physician would examine the referred infants presenting with complaints and clinical signs, and blood samples would be collected from sick infants for diagnosis of neonatal sepsis by performing sepsis screen and blood culture. Appropriate treatment would be provided as per hospital protocol. The study would be implemented as per the MRC guideline for the management of Global Health Trials in accordance with ICH-GCP and Indian Regulatory guidelines. A contract research organization would be engaged for comprehensive monitoring and quality assurance. The final analysis would be conducted in a blinded manner as per the statistical analysis plan (SAP) to estimate the primary outcomes of sepsis, possible serious bacterial infection (PSBI), and secondary outcomes. The codes will be broken after DMC permission. The protocol has been reviewed by the Research Ethics Committee of the Liverpool School of Tropical Medicine (REC-LSTM), from Research Ethics Committees of the six subject recruitment participating sites. DISCUSSION: This adequately powered and well-designed trial would conclusively answer the question whether probiotics can prevent neonatal sepsis in the high-risk group of low birth weight infants as indicated by a pilot study in 1340 LBW infants, evidence from systematic reviews of hospital-based studies, and a primary study on healthy newborns in Orissa. Results of the study would be generalizable to India and other low-middle-income countries. TRIAL REGISTRATION: Clinical Trial Registry of India (CTRI) CTRI/2019/05/019197 . Registered on 16 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sinha AP, Gupta SS, Poluru R, et al. Evaluating the efficacy of a multistrain probiotic supplementation for prevention of neonatal sepsis in 0-2-month-old low birth weight infants in India-the "ProSPoNS" Study protocol for a phase III, multicentric, randomized, double-blind, placebo-controlled trial. Trials. 2021. PMID: 33794969. doi:10.1186/s13063-021-05193-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。